Patents Assigned to Step Pharma S.A.S.
  • N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases
    Publication number: 20260159502
    Abstract: Compounds of formula (I) and related aspects.
    Type: Application
    Filed: October 14, 2025
    Publication date: June 11, 2026
    Applicant: Step Pharma S.A.S.
    Inventors: Abdul Quddus, Andrew Novak, David Cousin, Emma Blackham, Geraint Jones, Joseph Wrigglesworth, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed
  • Aminothiazole compounds as inhibitors of CTPS1
    Patent number: 12503466
    Abstract: Compounds of formula (I): (I) and related aspects.
    Type: Grant
    Filed: April 18, 2023
    Date of Patent: December 23, 2025
    Assignee: STEP PHARMA S.A.S.
    Inventors: Andrew Novak, Saleh Ahmed
  • N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases
    Patent number: 12466810
    Abstract: Compounds of formula (I) as human cytidine triphosphate synthase 1 (CTPS1) inhibitors for the treatment of proliferative diseases, such as e.g. cancer, such as e.g. leukemia and lymphoma, e.g. inflammatory skin diseases such as psoriasis, or e.g. multiple sclerosis. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 64 to 80; examples; biological examples 1 and 2; e.g. compounds P140, P231 to P263; tables 1 to 10). Specific examples are e.g.: N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido) pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide (Formula (II)), or 1-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)cyclohexane-1-carboxamide (Formula (III)).
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: November 11, 2025
    Assignee: Step Pharma S.A.S.
    Inventors: Abdul Quddus, Andrew Novak, David Cousin, Emma Blackham, Geraint Jones, Joseph Wrigglesworth, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed
  • Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors
    Patent number: 12371419
    Abstract: Compounds of formula (I), and related aspects.
    Type: Grant
    Filed: April 16, 2024
    Date of Patent: July 29, 2025
    Assignee: Step Pharma S.A.S.
    Inventor: Abdul Quddus
  • Compounds
    Patent number: 12319680
    Abstract: Compounds of formula (I) and related aspects.
    Type: Grant
    Filed: October 10, 2022
    Date of Patent: June 3, 2025
    Assignee: Step Pharma S.A.S.
    Inventors: Andrew Novak, Joseph Wrigglesworth
  • Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors
    Patent number: 11987573
    Abstract: Compounds of formula (I), and related aspects.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: May 21, 2024
    Assignee: Step Pharma S.A.S.
    Inventors: Abdul Quddus, Emma Blackham
  • Aminothiazole compounds as inhibitors of CTPS1
    Patent number: 11655246
    Abstract: Compounds of formula (I): (I) and related aspects.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: May 23, 2023
    Assignee: STEP PHARMA S.A.S.
    Inventors: Abdul Quddus, Andrew Novak, David Cousin, Elli Chatzopoulou, Emma Blackham, Geraint Jones, Jennifer Thomas, Joseph Wrigglesworth, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed
  • N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases
    Publication number: 20230086703
    Abstract: Compounds of formula (I) wherein ring B is selected from the group consisting of Formula (B-a) and Formula (B-bc) as human cytidine triphosphate synthase 1 (CTPS 1) inhibitors for the treatment of proliferative diseases, such as e.g. cancer, such as e.g. leukemia and lymphoma, e.g. inflammatory skin diseases such as psoriasis, or e.g. multiple sclerosis. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. page 129 to page 302; examples; biological examples 1 and 2; tables 1-17). Specific examples are e.g.: N-(4-(5-Chloropyridin-3-yl)phenyl)-2-(2-(cyclopropane-sulfonamido) pyrimidin-4-yl)butanamide (Formula P1) or 1-(2-(Cyclopropanesulfonamido)pyrimidin-4-yl)-N-(4-(6-ethoxypyrazin-2-yl)phenyl)cyclopentanecarboxamide (Formula P2).
    Type: Application
    Filed: June 4, 2020
    Publication date: March 23, 2023
    Applicant: Step Pharma S.A.S.
    Inventors: Abdul Quddus, Andrew Novak, David Cousin, Emma Blackham, Ellie Chatzopoulou, Geraint Jones, Jennifer Thomas, Joseph Wrigglesworth, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed, Gianna Toschi
  • SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS
    Publication number: 20230020663
    Abstract: The invention provides a compound of formula (I) and processes for the manufacture of such compounds, related intermediates, compositions comprising such compounds and the use of such compounds as cytidine triphosphate synthase 1 inhibitors, particularly in the treatment or prophylaxis of disorders associated with cell proliferation.
    Type: Application
    Filed: September 18, 2020
    Publication date: January 19, 2023
    Applicant: Step Pharma S.A.S.
    Inventors: Andrew Novak, Abdul Quddus, David Cousin, Joseph Wrigglesworth, Emma Blackham, Geraint Jones, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed
  • SULFONAMIDE DERIVATIVES AS CTPS1 INHIBITORS
    Publication number: 20230002352
    Abstract: The invention provides a compound of formula (I): formula (I) and the use of such compounds as cytidine triphosphate synthase 1 inhibitors, particularly in the treatment or prophylaxis of disorders associated with cell proliferation.
    Type: Application
    Filed: September 18, 2020
    Publication date: January 5, 2023
    Applicant: Step Pharma S.A.S.
    Inventors: Andrew Novak, Abdul Quddus, David Cousin, Joseph Wrigglesworth, Emma Blackham, Geraint Jones, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed
  • Compounds
    Patent number: 11505547
    Abstract: Compounds of formula (I) and related aspects.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: November 22, 2022
    Assignee: STEP PHARMA S.A.S.
    Inventors: Andrew Novak, Geraint Jones, Joseph Wrigglesworth, Lorna Duffy, Louise Birch, Pascal George
  • N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases
    Publication number: 20220324837
    Abstract: Compounds of formula (I) as human cytidine triphosphate synthase 1 (CTPS1) inhibitors for the treatment of prolifera-tive diseases, such as e.g. cancer, such as e.g. leukemia and lymphoma, e.g. inflammatory skin diseases such as psoriasis, or e.g. multiple sclerosis. The present description discloses the synthesis and characterisa-tion of exemplary compounds as well as pharmacological data thereof (e.g. pages 64 to 80; examples; biological examples 1 and 2; e.g. compounds P140, P231 to P263; tables 1 to 10). Specific examples are e.g.: N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonami-N do) pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide (Formula (II)), or 1-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)cyclohexane-1-carboxamide (Formula (III)).
    Type: Application
    Filed: June 4, 2020
    Publication date: October 13, 2022
    Applicant: Step Pharma S.A.S.
    Inventors: Abdul Quddus, Andrew Novak, David Cousin, Emma Blackham, Geraint Jones, Joseph Wrigglesworth, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed
  • Compounds
    Publication number: 20210387965
    Abstract: Compounds of formula (I), and related aspects.
    Type: Application
    Filed: October 23, 2019
    Publication date: December 16, 2021
    Applicant: Step Pharma S.A.S.
    Inventors: Abdul Quddus, Andrew Novak, David Cousin, Emma Blackham, Geraint Jones, Joseph Wrigglesworth, Lorna Duffy, Louise Birch, Pascal George, Saleh Ahmed